Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2021 Earnings Conference Call August 10, 2021 4:30 PM ET Company Participants Timothy McCarthy - LifeSci Advisors Sergio Traversa - CEO & Director Charles Ence - Chief Accounting & Compliance Officer Charles Gorodetzky - Former Scientific Director, National Institute of Drug Abuse Addiction Research Center Conference Call Participants Marc Goodman - SVB Leerink Andrea Tan - Goldman Sachs Group Joon Lee - Truist Securities Jay Olson - Oppenheimer Eddie Hickman - Gu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) | Nevada | 45-5401931 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Employer | FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ ...

1 Targeting Major Advances in Treatment of CNS Disorders June 2021 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," ...

Financial Data and Key Metrics Changes - For Q1 2021, total research and development expenses were approximately $14 million, up from $4.5 million in Q1 2020, primarily due to increased costs associated with the broader clinical program for REL-1017 [14] - General and administrative expenses for Q1 2021 were approximately $8.4 million, compared to $5.5 million in the same period of 2020, mainly due to an increase in stock-based compensation [15] - The net loss for Q1 2021 was approximately $22.2 million, or $1.34 per share, compared to a net loss of $10.7 million, or $0.72 per share, in Q1 2020 [16] - As of March 31, 2021, the company had cash, cash equivalents, and short-term investments of approximately $102.7 million, down from $117.1 million on December 31, 2020 [17] Business Line Data and Key Metrics Changes - The ongoing RELIANCE program for REL-1017 is designed to evaluate its efficacy as an adjunctive treatment for major depressive disorder (MDD) [6][9] - The first phase 3 trial, RELIANCE I, continues to enroll participants as expected, with additional sites coming online [9] - The second phase 3 trial, RELIANCE II, has also begun enrolling participants, with top-line data expected in the first half of the following year [9] Market Data and Key Metrics Changes - The company is experiencing an increase in patient enrollment due to the rise in depression cases following the COVID-19 pandemic [70] - The REL-1017 development program remains active, with multiple key data results anticipated over the next 12 months [21] Company Strategy and Development Direction - The company plans to initiate a study evaluating REL-1017 as a monotherapy for MDD within the current quarter, with completion anticipated by year-end 2021 [11] - The management emphasizes the importance of differentiating REL-1017 from traditional antidepressants by highlighting its unique mechanism of action and safety profile [60][64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong cash position supporting the company through multiple anticipated data readouts in the first half of 2022 [17] - The management team remains optimistic about the clinical development of REL-1017 and its potential to address unmet needs in the treatment of depression [21] Other Important Information - The company has presented nine posters across three different scientific congresses, showcasing data that supports the safety and efficacy of REL-1017 [14][18] - The management is actively working on studies to assess the human abuse potential of REL-1017, with plans to complete these studies by the end of 2021 [12][13] Q&A Session Summary Question: Can you describe how similar s-methadone should be to placebo on the likability score? - Management indicated that while oxycodone is expected to be liked by participants, they do not anticipate s-methadone to be significantly different from placebo [25] Question: If the data is positive, would it be fair for investors to assume the second abuse level study will yield similar results? - Management believes that the drug's mechanism of action suggests it is unlikely to show dissociative or hallucination effects, supporting a positive outlook for the second study [27] Question: What is the basis for the DEA's claim regarding dextromethadone's addiction liability? - Management stated that the DEA based its claim on available literature and previous studies conducted by the company [32] Question: How do the studies help from a scheduling perspective? - Management explained that if the data shows a statistically significant difference from oxycodone, it is unlikely to be classified as a Schedule II drug [44] Question: Can you provide details on the monotherapy study and FDA feedback? - Management indicated that the monotherapy protocol is similar to the RELIANCE I and II studies, with a larger patient population expected for recruitment [48] Question: Will the findings from the APA influence the design of the monotherapy trial? - Management confirmed that the findings would not influence the trial design, as they aim to mimic a standard population without pre-selection [53]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000- 55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 45-5401931 | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K New York, NY 10022 (Address of principal executive offices) (Zip Code) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 45-5401931 | | --- | - ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2020 Earnings Conference Call March 23, 2021 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Marc Goodman - Leerink Joon Lee - Truist Securities Jay Olson - Oppenheimer Operator Greetings. Welcome to the Relmada Therapeutics Incorporated Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this t ...

Targeting Major 2020 Corporate Presentation I CNS Disorders Advances in Treatment of December 2020 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. The ...

Targeting Major 2020 Corporate Presentation I CNS Disorders Advances in Treatment of November 2020 I Nasdaq: RLMD Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements." These statements can be identified by the fact that they do not relate strictly to historic or current facts. The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission File Number: 000- 55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its c ...